Navigation Links
Study shows surgery provides good long-term outcomes for patients with gastrointestinal cancers
Date:1/14/2009

CHICAGO (January 14, 2009) New research published in the January issue of the Journal of the American College of Surgeons shows that laparoscopic removal of gastrointestinal stromal tumors (GISTs) is safe and effective, with a disease-free survival rate of nearly 80 percent after an average follow-up time of three and a-half years.

GIST is a type of cancer arising from special cells in the wall of the gastrointestinal tract that help coordinate the muscular movement of digestive organs. Each year, between 4,500 and 6,000 cases of GIST are diagnosed in the United States. Laparoscopic surgery is an attractive alternative to traditional "open" surgery the treatment of choice for GISTs that have not spread to nearby organs since it is requires smaller abdominal incisions and therefore may be safer and result in a quicker recovery.

"Based on our data, which represents the largest retrospective series of GIST patients reported to date, we believe that laparoscopic resection is feasible in the management of these tumors, carries no additional risks and has comparable results to the open approach," said Celia Divino, MD, FACS, Chief, Division of General Surgery at The Mount Sinai Medical Center, New York, N.Y.

Parissa Tabrizian, MD, further noted that, "The biologic behavior of GISTs makes them amenable to laparoscopic resection because they do not require removal of large amounts of tissue or lymph nodes."

Researchers conducted a retrospective study to evaluate long-term outcomes and survival in 76 patients who underwent laparoscopic treatment of GIST. Tumors were located in the stomach (72 percent) and the small bowel (28 percent).

At a mean follow-up of 41 months (range, 3 to 102 months), the overall disease-free survival rate was 78 percent (77 percent for gastric tumors and 82 percent for small bowel tumors). Three percent of patients died of metastatic disease, and nine percent of patients died from other unrelated causes. In comparison with patients with gastric GISTs, those with small bowel tumors had overall better outcomes, with no deaths or disease recurrence. Recurrent disease was seen in four patients with gastric tumors, and there was disease-specific mortality in two patients. There was no difference in overall survival between patients with small bowel and gastric tumors (89.5 percent versus 88.7 percent, respectively, p>0.165).


'/>"/>

Contact: Sally Garneski, ACS
pressinquiry@facs.org
312-202-5409
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. TPHAC Reaction to Economic Impact Study
2. First-of-Its Kind Study: Medicare for All (Single-Payer) Reform Would Be Major Stimulus for Economy With 2.6 Million New Jobs, $317 Billion in Business Revenue, $100 Billion in Wages
3. National Children's Study Begins Recruiting Volunteers
4. Study shows workplace benefits of influenza vaccination in 50-64 year olds
5. Study: Most young violent offenders in two NYC neighborhoods have seen someone killed
6. National Childrens Study Begins Recruiting Volunteers
7. InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA
8. UNC study supports role of circadian clock in response to chemotherapy
9. Medical study shows epidurals and spinal anesthetics are safer than previously reported
10. InterMune Reports Results from Triple Combination Study of ITMN-191
11. LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading ... Denise Flannery, to its strategic advisory and client development team. , In ... with clients across different industries to develop and implement market-justified strategies, modernize and ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... has joined its executive team as the President of its HealthBI division. ... management systems and contact centers. , “Scott is a utility player who ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced ... When we’re born, Nature gives us a full supply of melanin – in ... continuously lose this natural glare-reducing pigment; however, around the age of thirty, we develop ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bringing ... the MirixaPro 6.0 platform. As the industry’s leading Medication Therapy Management solution, ... Based on industry research and market feedback, the latest version of MirixaPro ...
(Date:9/19/2017)... ... 2017 , ... Back Pain Centers of America ... with a reputable physician in their area, announces the addition of Allegion Spine ... Spine Clinic was founded by board-certified spine surgeon, Jaswinder Grover, M.D. , ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a ... created a vibrant charitable donation program -- "Color ... support congenital heart defect research by The Children,s ... and the general public are encouraged to download ... submit the completed artwork to the gallery on ...
Breaking Medicine Technology: